All In Biotech

NDA 022165 · Cosette

Cambia

Diclofenac Potassium · Oral

Last checked: Nov 20, 2026Latest source record: Nov 21, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Jun 17, 2009

Approved uses

1

Original approval plus efficacy supplements

Registered trials

492

123 Phase 3, 29 recruiting

FAERS reports

10,696

8,489 serious, 4,383 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [ see Warnings and Precautions ( 5.1 ) ]. CAMBIA is contraindicated in the setting of coronary artery bypass graft (CABG) surgery [ see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 ) ]. Gastrointestinal Bleeding, Ulceration, and Perforation NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with...

What it is approved for

From the label in effect Dec 11, 2024.

CAMBIA is indicated for the acute treatment of migraine attacks with or without aura in adults (18 years of age or older). Limitations of Use: CAMBIA is not indicated for the prophylactic therapy of migraine. The safety and effectiveness of CAMBIA have not been established for cluster headache, which is present in an older, predominantly male population. CAMBIA is a non-steroidal anti-inflammatory drug (NSAID) indicated for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older ( 1 ) Limitations of Use ( 1 ): CAMBIA is not indicated for the prophylactic therapy of migraine Safety and effectiveness of CAMBIA not established for cluster headache, which is present in an older, predominantly male population

Mechanism: CAMBIA has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of CAMBIA, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Diclofenac is a potent inhibitor of prostaglandin synthesis in vitro. Diclofenac concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because diclofenac is an inhibitor of prostaglandin synthesis, its...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • CAMBIA · DICLOFENAC POTASSIUM 50MG · FOR SOLUTION, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Diclofenac" as an intervention, any sponsor and status, largest first.

All 492 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective2,897
  • rheumatoid arthritis2,674
  • fatigue2,642
  • off label use2,597
  • pain2,541
  • rash2,540
  • systemic lupus erythematosus2,494
  • joint swelling2,437
  • wound2,383
  • pemphigus2,317
  • glossodynia2,295
  • synovitis2,293

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20044
20059
200659
20079
200816
200914
201015
201166
201245
201354
201471
2015205
2016894
2017511
2018486
2019642
2020597
2021499
2022689
2023845
20242,081
20251,931
2026954

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cambia (Diclofenac Potassium)

2024 spending

$1.3M

Beneficiaries

264

1,103 claims

Per beneficiary

$5,102

$93.21 per unit

View as table
YearSpending
2020$7,032,916
2021$6,823,634
2022$6,277,481
2023$2,474,537
2024$1,347,019

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,439 on PubMed

Sponsor: Cosette

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.